MAP2K1 and neoplasm: In order to test if blocking of MEK1, JNK or mTOR downstream of EGFR would mimic the results obtained when treating the cells with cetuximab, the tumor cells were incubated with cetuximab and/or one of the chemical inhibitors PD98059 (MEK), SP600125 (JNK) and Rapamycin (mTOR) and then stimulated with IFNγ/TNFα.